# US 2012/0251999 A1 · Vitrification systems and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251999 A1
- Document ID: US20120251999A1
- Status: Published application
- Kind: A1
- Application number: 13/364,143
- Filed: 2012-02-01
- Published: 2012-10-04
- Earliest claimed: 2011-02-01
- Assignees: The Brigham and Women's Hospital, Inc.
- Inventors: Utkan DEMIRCI; Emre KAYAALP; Sangjun MOON; Young Seok SONG; Xiaohui ZHANG
- Web page: https://patentgrep.com/patent/US20120251999A1

## CPC

- G01N 1/42: Low-temperature sample treatment, e.g. cryofixation
- A01N 1/142: Apparatus
- Y10T 436/2525: Stabilizing or preserving
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The embodiments of the invention described herein relate to systems and methods for the vitrification of biological samples. Vitrification is achieved by generating nanodroplets of a solution comprising the biological sample with a means that can be automated and adapted to high-throughput applications.

## Claims

### Claim 1

A method of vitrifying a biological sample comprising;
generating nanodroplets of a solution comprising the biological sample; and contacting the nanodroplets with a cooling agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the biological sample is selected from the group consisting of:
cells; biological fluids; biopsy samples; diagnostic samples; blood; urine; and protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein the cells are selected from the group consisting of:
gametes; sperm; eggs; embryos; zygotes; chondrocytes; red blood cells; blood cells, hepatic cells, fibroblasts, stem cells; cord blood cells; adult stem cells, induced pluripotent stem cells, autologous cells; autologous stem cells; bone marrow cells; hematopoietic cells; embryonic stem cells; and hematopoietic stem cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the nanodroplets have a volume of less than 500 nL.

### Claim 5 (depends on 1)

The method of claim 1, wherein the nanodroplets have a volume of less than 100 nL.

### Claim 6 (depends on 1)

The method of claim 1, wherein the nanodroplets have a volume of less than 10 nL.

### Claim 7 (depends on 1)

The method of claim 1, wherein the solution comprising the biological sample further comprises at least one cryoprotective agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the cryoprotective agent is selected from the group consisting of:
dimethylsulphoxide (DMSO), 1,2-propanediol (PROH), ethylene glycol (EG), sucrose, trehalose; mannitol; ectoin; methylcellulose; polyethylene glycol (PEG); and naturally occurring cyroprotectants.

### Claim 9 (depends on 7)

The method of claim 7, wherein the cryoprotective agent is present at a concentration of less than 6 M.

### Claim 10 (depends on 7)

The method of claim 7, wherein the cryoprotective agent is present at a concentration of less than 3 M.

### Claim 11 (depends on 7)

The method of claim 7, wherein the cryoprotective agent is present at a concentration of less than 2 M.

### Claim 12 (depends on 1)

The method of claim 1, wherein the solution comprising the biological sample further comprises a hydrogel.

### Claim 13 (depends on 1)

The method of claim 1, wherein the nanodroplets are generated by causing the solution comprising the biological sample to flow through a nozzle of a reservoir.

### Claim 14 (depends on 13)

The method of claim 13, wherein the solution comprising the biological sample is caused to flow through the nozzle of the reservoir via a means selected from the group consisting of:
a plunger; a solenoid-controlled plunger; co-flow of a gas; an inkjet, and spraying.

### Claim 15 (depends on 1)

The method of claim 1, wherein the means of generating the nanodroplets is an acoustic generator.

### Claim 16 (depends on 1)

The method of claim 1, wherein the means of generating nanodroplets is automated.

### Claim 17 (depends on 1)

The method of claim 1, wherein the nanodroplets are contacted with the cooling agent by allowing the nanodroplets to fall from the nozzle into or onto a cooling agent.

### Claim 18 (depends on 1)

The method of claim 1, wherein the nanodroplets are contacted with the cooling agent by allowing the nanodroplets to fall from the nozzle onto a collection membrane and then contacting the collection membrane with the cooling agent.

### Claim 19 (depends on 1)

The method of claim 1, wherein the cooling agent is selected from the group consisting of:
liquid nitrogen, nitrogen vapor, liquid helium, and helium vapor.

### Claim 20 (depends on 1)

The method of claim 1, further comprising storing the vitrified biological sample at a temperature lower than −130° C.

### Claim 21 (depends on 1)

The method of claim 1, further comprising generating the nanodroplets in a high throughput system.

### Claim 22 (depends on 21)

The method of claim 21, wherein the high throughput system comprises a reservoir with multiple nozzles.

### Claim 23 (depends on 21)

The method of claim 21, wherein the high throughput system comprises multiple reservoirs.

### Claim 24 (depends on 1)

The method of claim 1, further comprising causing the vitrified biological sample to warm rapidly.

### Claim 25

A system for vitrifying a biological sample comprising;
a reservoir containing the biological sample;
a means of forming the biological sample into nanodroplets and directing the nanodroplets to flow or fall towards a catchment;
a catchment for collecting the nanodroplets.

### Claim 26 (depends on 25)

The system of claim 25, wherein the means of forming the biological sample into nanodroplets comprises causing a solution comprising the biological sample to flow through a nozzle.

### Claim 27 (depends on 26)

The system of claim 26, wherein a means of causing the solution comprising the biological sample to flow through the nozzle connected to the reservoir is selected from a group consisting of:
a plunger; a solenoid-controlled plunger; a gas co-flow muzzle; and spraying.

### Claim 28 (depends on 25)

The system of claim 25, wherein the means of forming the biological sample into the nanodroplets is an acoustic generator.

### Claim 29 (depends on 25)

The system of claim 25, wherein the means of forming the biological sample into the nanodroplets is automated.

### Claim 30 (depends on 26)

The system of claim 26, wherein a terminus of the nozzle is less than 200 μm in diameter.

### Claim 31 (depends on 25)

The system of claim 25, wherein the catchment comprises a cooling agent.

### Claim 32 (depends on 31)

The system of claim 31, wherein the cooling agent is selected from the group consisting of:
liquid nitrogen, nitrogen vapor, liquid helium, and helium vapor.

### Claim 33 (depends on 25)

The system of claim 25, wherein the catchment comprises a collection membrane.

### Claim 34 (depends on 25)

The system of claim 25, wherein the nanodroplets have a volume of less than 500 nL.

### Claim 35 (depends on 25)

The system of claim 25, wherein the nanodroplets have a volume of less than 100 nL.

### Claim 36 (depends on 25)

The system of claim 25, wherein the nanodroplets have a volume of less than 10 nL.

### Claim 37 (depends on 25)

The system of claim 25, wherein the biological sample further comprises at least one cryoprotective agent.

### Claim 38 (depends on 37)

The system of claim 37, wherein the cryoprotective agent is selected from the group consisting of:
dimethylsulphoxide (DMSO), 1,2-propanediol (PROH), ethylene glycol (EG), sucrose, trehalose; mannitol; ectoin; methylcellulose; polyethylene glycol (PEG); and naturally occurring cyroprotectants.

### Claim 39 (depends on 37)

The system of claim 37, wherein the cryoprotective agent is present at a concentration of less than 6 M.

### Claim 40 (depends on 37)

The system of claim 37, wherein the cryoprotective agent is present at a concentration of less than 3 M.

### Claim 41 (depends on 37)

The system of claim 37, wherein the cryoprotective agent is present at a concentration of less than 2 M.

### Claim 42 (depends on 25)

The system of claim 25, wherein the biological sample further comprises a hydrogel.

### Claim 43 (depends on 25)

The system of claim 25, wherein the system is a high throughput system.

### Claim 44 (depends on 43)

The system of claim 43, wherein the reservoir of the high throughput system comprises multiple nozzles.

### Claim 45 (depends on 44)

The system of claim 44, wherein the high throughput system comprises multiple reservoirs.
